APA (7th ed.) Citation

Jelínek, T., Maisnar, V., Pour, L., Špička, I., Minařík, J., Gregora, E., . . . Hájek, R. (2018). Adjusted comparison of daratumumab monotherapy versus real-world historical control data from the Czech Republic in heavily pretreated and highly refractory multiple myeloma patients. Current Medical Research & Opinion, 34(5), 775. https://doi.org/10.1080/03007995.2017.1410121

Chicago Style (17th ed.) Citation

Jelínek, Tomáš, et al. "Adjusted Comparison of Daratumumab Monotherapy Versus Real-world Historical Control Data from the Czech Republic in Heavily Pretreated and Highly Refractory Multiple Myeloma Patients." Current Medical Research & Opinion 34, no. 5 (2018): 775. https://doi.org/10.1080/03007995.2017.1410121.

MLA (9th ed.) Citation

Jelínek, Tomáš, et al. "Adjusted Comparison of Daratumumab Monotherapy Versus Real-world Historical Control Data from the Czech Republic in Heavily Pretreated and Highly Refractory Multiple Myeloma Patients." Current Medical Research & Opinion, vol. 34, no. 5, 2018, p. 775, https://doi.org/10.1080/03007995.2017.1410121.